<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nelarabine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nelarabine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nelarabine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9466" href="/d/html/9466.html" rel="external">see "Nelarabine: Drug information"</a> and <a class="drug drug_patient" data-topicid="11562" href="/d/html/11562.html" rel="external">see "Nelarabine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709168"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Neurologic adverse reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe neurologic adverse reactions have been reported with the use of nelarabine. These reactions have included altered mental states, including severe somnolence; CNS effects, including convulsions; and peripheral neuropathy, ranging from numbness and paresthesias to motor weakness and paralysis. There have also been reports of adverse reactions associated with demyelination and ascending peripheral neuropathies similar in appearance to Guillain-Barr√© syndrome.</p>
<p style="text-indent:-2em;margin-left:2em;">Full recovery from these reactions has not always occurred with cessation of therapy with nelarabine. Monitor frequently for signs and symptoms of neurologic toxicity during treatment with nelarabine. Discontinue nelarabine for neurologic reactions of National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) grade 2 or greater.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F1987961"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Arranon</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868717"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Atriance</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F4288457"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Antimetabolite</span></li></ul></div>
<div class="block dop drugH1Div" id="F1987994"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing and frequency may vary by protocol and/or treatment phase; refer to specific protocol. Adequate IV hydration and prophylactic antihyperuricemic therapy are recommended to prevent tumor lysis syndrome.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b63c5319-ebdc-44ec-8519-7e59abc98a87">T-cell acute lymphoblastic leukemia; newly diagnosed, high risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>T<b>-cell acute lymphoblastic leukemia (T-ALL)</b>; newly diagnosed, high risk:</b> Limited data available: <b>Note:</b> Nelarabine was not administered within 2 weeks of other chemotherapies known to cause central or peripheral toxicities.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Consolidation</i>: 650 mg/m<sup>2</sup>/dose on days 1 through 5 and 43 through 47 of a 77-day cycle (in combination with vincristine, pegaspargase, cyclophosphamide, cytarabine, mercaptopurine, and intrathecal methotrexate) (Winter 2015; Winter 2018).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Delayed intensification</i>: 650 mg/m<sup>2</sup>/dose on days 29 through 33 of a 63-day cycle (in combination with vincristine, dexamethasone, pegaspargase, cyclophosphamide, cytarabine, thioguanine, doxorubicin, and intrathecal methotrexate) (Winter 2015; Winter 2018).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance:</i> 650 mg/m<sup>2</sup>/dose on days 29 through 33 of an 84-day cycle; during first 3 cycles only (in combination with vincristine, mercaptopurine, prednisone, oral methotrexate, and intrathecal methotrexate) (Winter 2015; Winter 2018).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4262d55f-73eb-47af-bac0-e8ce78b5d1a8">T-cell acute lymphoblastic leukemia, T-cell lymphoblastic lymphoma; relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>T-cell acute lymphoblastic leukemia (T-ALL), T-cell lymphoblastic lymphoma; relapsed/refractory:</b> Children and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Monotherapy:</i> 650 mg/m<sup>2</sup>/dose on days 1 through 5; repeat cycle every 21 days until transplant, disease progression, or unacceptable toxicity (Zwaan 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Combination therapy</i>: Limited data available: 650 mg/m<sup>2</sup>/dose for 5 consecutive days (in combination with etoposide and cyclophosphamide) for up to 2 cycles. In the clinical trial, nelarabine was administered either before (days 1 through 5) or 1 to 2 days after other chemotherapy (days 7 or 8 through 11 or 12) (in combination with etoposide and cyclophosphamide) for up to 2 cycles (Commander 2010).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for toxicity:</b> Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Neurologic toxicity ‚â• grade 2: Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic or other (non-neurologic) toxicity: Consider treatment delay.</p></div>
<div class="block dorp drugH1Div" id="F51130674"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">All patients:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ‚â•50 mL/minute: No adjustment necessary</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;50 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (although ARA-G clearance is decreased as renal function declines, data is insufficient for a dosing recommendation); monitor closely.</p></div>
<div class="block dohp drugH1Div" id="F51130675"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); closely monitor with severe impairment (total bilirubin &gt;3 times ULN).</p></div>
<div class="block doa drugH1Div" id="F1987995"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9466" href="/d/html/9466.html" rel="external">see "Nelarabine: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Adequate hydration and prophylactic antihyperuricemic therapy are recommended to prevent tumor lysis syndrome.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1f562c02-7510-4169-9744-decdd90420ba">T-cell acute lymphoblastic leukemia/lymphoma, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>T-cell acute lymphoblastic leukemia/lymphoma, relapsed/refractory: IV:</b> 1,500 mg/m<sup>2</sup>/dose on days 1, 3, and 5; repeat every 21 days until a transplant candidate, disease progression, unacceptable toxicity, or until no longer benefiting from therapy.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991826"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ‚â•50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;50 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling, (although ARA-G clearance is decreased as renal function declines, data is insufficient for a dosing recommendation); monitor closely.</p></div>
<div class="block doha drugH1Div" id="F50989107"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); closely monitor with severe impairment (total bilirubin &gt;3 times ULN).</p></div>
<div class="block adr drugH1Div" id="F1987976"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (adults: 15%), edema (adults: 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Fatigue (adults: 50%), drowsiness (adults: 23%; children and adolescents: 7%), dizziness (adults: 21%), hypoesthesia (adults: 17%; children and adolescents: 6%), headache (15% to 17%), paresthesia (adults: 15%; children and adolescents: 4%), peripheral sensory neuropathy (6% to 13%; children and adolescents, grade 3: 6%), pain (adults: 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum potassium (children and adolescents: 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (adults: 41%), diarrhea (adults: 22%), vomiting (adults: 22%; children and adolescents: 10%), constipation (adults: 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (95% to 99%; children and adolescents, grade 3: 45%; adults, grade 3: 20%; grades ‚â•4: 10% to 14%), neutropenia (children and adolescents: 94%; adults: 81%; grade 3: 14% to 17%, children and adolescents, grades ‚â•4: 62%, adults, grades ‚â•4: 49%), thrombocytopenia (86% to 88%; adults, grade 3: 37%; children and adolescents, grade 3: 27%; children and adolescents, grades ‚â•4: 32%; adults, grades ‚â•4: 22%), leukopenia (children and adolescents: 38%; children and adolescents, grade 3: 14%; children and adolescents, grades ‚â•4: 7%), febrile neutropenia (adults: 12%; adults, grade 3: 9%; adults, grades ‚â•4: 1%), petechia (adults: 12%; adults, grade 3: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (children and adolescents: 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (adults: 17%; children and adolescents: 6%), myalgia (adults: 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (adults: 25%), dyspnea (adults: 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (adults: 23%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (adults: 8%), sinus tachycardia (adults: 8%), chest pain (adults: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Ataxia (adults: 9%; children and adolescents: 2%), confusion (adults: 8%), myasthenia (adults: 8%), rigors (adults: 8%), insomnia (adults: 7%), peripheral motor neuropathy (4% to 7%; grade 3: 1% to 2%), abnormal gait (adults: 6%), depression (adults: 6%), impaired consciousness (adults: 6%), seizure (children and adolescents: 6%; adults, grade 3: 1%), peripheral neuropathy (5% to 6%; grade 3: 1% to 2%), noncardiac chest pain (adults: 5%), motor dysfunction (children and adolescents: 4%), neuropathy (adults: 4%), amnesia (adults: 3%), balance impairment (adults: 2%), abnormal sensory symptoms (1% to 2%), aphasia (adults, grade 3: 1%), burning sensation (adults: 1%), cerebral hemorrhage (adults, grade 4: 1%), cranial nerve palsy (third and sixth nerve, children and adolescents: 1%), coma (adults, grade 4: 1%), disturbance in attention (adults: 1%), dysarthria (1%), encephalopathy (children and adolescents, grade 4: 1%), hemiparesis (adults, grade 3: 1%), hydrocephalus (children and adolescents: 1%), hypertonia (children and adolescents, grade 3: 1%), hyporeflexia (1%), intracranial hemorrhage (adults, grade 4: 1%), lethargy (children and adolescents: 1%), leukoencephalopathy (adults, grade 4: 1%), loss of consciousness (adults, grade 3: 1%), mental status changes (children and adolescents: 1%), nerve palsy (adults: 1%), paralysis (children and adolescents: 1%), neuralgia (adults: 1%), sciatica (adults: 1%), speech disturbance (adults: 1%), status epilepticus (children and adolescents: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum albumin (children and adolescents: 10%), decreased serum calcium (children and adolescents: 8%), dehydration (adults: 7%), decreased serum glucose (children and adolescents: 6%), decreased serum magnesium (children and adolescents: 6%), hyperglycemia (adults: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (adults: 9%), anorexia (adults: 9%), stomatitis (adults: 8%; grade 3: 1%), abdominal distention (adults: 6%), dysgeusia (adults: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin (children and adolescents: 10%), increased serum aspartate aminotransferase (adults: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (5% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (adults: 9%), back pain (adults: 8%), limb pain (adults: 7%), tremor (4% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (adults: 4%), nystagmus disorder (adults: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (children and adolescents: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pleural effusion (adults: 10%), epistaxis (adults: 8%), pneumonia (adults: 8%), dyspnea on exertion (adults: 7%), sinusitis (adults: 7%), wheezing (adults: 5%), sinus headache (adults: 1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Demyelinating disease, increased creatine phosphokinase in blood specimen, opportunistic infection, progressive multifocal leukoencephalopathy, rhabdomyolysis, tumor lysis syndrome</p></div>
<div class="block coi drugH1Div" id="F1987972"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-4em;margin-left:4em;">
<i>Canadian labeling:</i> Hypersensitivity to nelarabine or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F1987973"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">‚Ä¢ Bone marrow suppression: Leukopenia, thrombocytopenia, anemia, and neutropenia (including neutropenic fever) are associated with nelarabine treatment. Monitor blood counts regularly.</p>
<p style="text-indent:-2em;margin-left:4em;">‚Ä¢ CNS depression: Nelarabine may cause somnolence during and for several days after treatment, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">‚Ä¢ Hepatitis B virus screening: The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:4em;">‚Ä¢ Neurotoxicity: <b>[US Boxed Warning]: Severe neurotoxicities, including mental status changes, severe somnolence, seizures, and peripheral neuropathy (ranging from numbness and paresthesias to motor weakness and paralysis), have been reported. Monitor frequently during treatment for signs and symptoms of neurotoxicity; discontinue if ‚â• grade 2. Adverse reactions associated with demyelination and ascending peripheral neuropathies similar in appearance to Guillain-Barr√© syndrome have also been reported. Neurologic toxicities may not fully return to baseline after treatment cessation.</b> Common signs and symptoms of neurotoxicity include somnolence, headache, paresthesia, dysesthesia, dizziness, neuropathy (sensory and motor), cerebellar disturbances, tremor, and, in severe cases, coma, status epilepticus, craniospinal demyelination, and ascending neuropathy. Symptom onset from start of first infusion is often within a median of 5 to 8 days (range: 1 to 269 days), with a median duration of 2 to 6 days (range: 1 to 393 days). Monitor closely for neurologic toxicity during and for at least 24 hours after each treatment. Risk of neurotoxicity may be increased in patients with concurrent or previous intrathecal chemotherapy or prior craniospinal irradiation.</p>
<p style="text-indent:-2em;margin-left:4em;">‚Ä¢ Tumor lysis syndrome: Tumor lysis syndrome (TLS) may occur as a consequence of leukemia treatment. May lead to life-threatening acute renal failure. Ensure adequate hydration prior to and during treatment to prevent hyperuricemia and TLS; consider prophylactic antihyperuricemic therapy. Monitor closely.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">‚Ä¢ Hepatic impairment: Monitor closely for toxicities. Risk of adverse reactions may be higher with severe hepatic dysfunction.</p>
<p style="text-indent:-2em;margin-left:4em;">‚Ä¢ Renal impairment: Monitor closely for toxicities. Ara-G clearance may be reduced with renal dysfunction and the risk of adverse reactions may be higher in patients with moderate to severe impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">‚Ä¢ Vaccines: Avoid administration of live vaccines to immunocompromised patients.</p></div>
<div class="block foc drugH1Div" id="F1988006"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Arranon: 5 mg/mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/mL (50 mL)</p></div>
<div class="block geq drugH1Div" id="F1987963"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16322890"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Arranon Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/mL (per mL): $19.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Nelarabine Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/mL (per mL): $15.84 - $15.86</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868718"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Atriance: 5 mg/mL (50 mL)</p></div>
<div class="block adip drugH1Div" id="F53569393"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Intravenous nelarabine solution contains 4.5 mg of sodium chloride per mL.</p></div>
<div class="block admp drugH1Div" id="F52614171"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Adequate IV hydration and prophylactic antihyperuricemic therapy may be considered to prevent tumor lysis syndrome.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Infuse doses over 1 hour.</p></div>
<div class="block adm drugH1Div" id="F1988000"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Adequate IV hydration and prophylactic antihyperuricemic therapy are recommended to prevent tumor lysis syndrome.</p>
<p style="text-indent:-2em;margin-left:2em;">Infuse over 2 hours on days 1, 3, and 5.</p></div>
<div class="block hazard drugH1Div" id="F49132770"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block sts drugH1Div" id="F1987982"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 25¬∞C (77¬∞F); excursions permitted to 15¬∞C to 30¬∞C (59¬∞F to 86¬∞F). Stable upon preparation in a polyvinylchloride infusion bag or a glass container for up to 8 hours at up to 30¬∞C (86¬∞F). Extended stability information may be available (Kaiser 2011).</p></div>
<div class="block usep drugH1Div" id="F53569960"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma following treatment with at least 2 chemotherapy regimens (FDA approved in ages ‚â•1 year and adults).</p></div>
<div class="block mst drugH1Div" id="F3401809"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Nelarabine may be confused with clofarabine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299749"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F1987980"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within ‚ÄúCYP3A4 Inducers [Strong]‚Äù are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the ‚ÄúLaunch drug interactions program‚Äù link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentostatin: May decrease serum concentrations of the active metabolite(s) of Nelarabine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49308490"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status in females of reproductive potential prior to therapy initiation. Females of reproductive potential should use effective contraception during nelarabine therapy. Male patients (including those who have had vasectomies) with female partners of reproductive potential should use condoms during nelarabine treatment and for 3 months after the last nelarabine dose.</p></div>
<div class="block pri drugH1Div" id="F1987970"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on its mechanism of action and findings in animal reproduction studies, nelarabine may cause fetal harm if administered during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). In general, if chemotherapy is indicated, it should be avoided during the first trimester, there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation. Specific use of nelarabine is not discussed (ESMO [Peccatori 2013]).</p></div>
<div class="block mopp drugH1Div" id="F53569959"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor closely for neurologic toxicity (severe somnolence, seizure, peripheral neuropathy, confusion, ataxia, paresthesia, hypoesthesia, coma, or craniospinal demyelination), especially during and for at least 24 hours after each treatment; signs and symptoms of tumor lysis syndrome; hydration status; CBC with platelet counts; renal and liver function tests; verify pregnancy status prior to therapy initiation in females of reproductive potential.</p></div>
<div class="block pha drugH1Div" id="F1987985"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Nelarabine, a prodrug of ara-G, is demethylated by adenosine deaminase to ara-G and then converted to ara-GTP. Ara-GTP is incorporated into the DNA of the leukemic blasts, leading to inhibition of DNA synthesis and inducing apoptosis. Ara-GTP appears to accumulate at higher levels in T-cells, which correlates to clinical response.</p></div>
<div class="block phk drugH1Div" id="F1987987"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>ss</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Nelarabine: Pediatric patients: 213 ¬± 358 L/m<sup>2</sup>; Adults: 197 ¬± 216 L/m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:4em;">Ara-G: Pediatric patients: 33 ¬± 9.3 L/m<sup>2</sup>; Adults: 50 ¬± 24 L/m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Nelarabine and Ara-G: &lt;25%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; demethylated by adenosine deaminase to form ara-G (active); also hydrolyzed to form methylguanine. Both ara-G and methylguanine metabolized to guanine. Guanine is deaminated into xanthine, which is further oxidized to form uric acid, which is then oxidized to form allantoin.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Pediatric patients: Nelarabine: 13 minutes, Ara-G: 2 hours; Adults: Nelarabine: 18 minutes, Ara-G: 3.2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Ara-G: Adults: 3 to 25 hours (of day 1)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (nelarabine 5% to 10%, Ara-G 20% to 30%)</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Nelarabine clearance is ~30% higher in pediatric patients (259 ¬± 409 L/hour/m<sup>2</sup>) than in adults (197 ¬± 189 L/hour/m<sup>2</sup>); Ara-G clearance in pediatric patients (11.3 ¬± 4.2 L/hour/m<sup>2</sup>) is similar to adults (10.5 ¬± 4.5 L/hour/m<sup>2</sup>)</p></div>
<div class="block phksp drugH1Div" id="F51154888"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance of Ara-G is reduced 15% in patients with mild renal impairment (CrCl 50 to 80 mL/minute) and 40% in patients with moderate renal impairment (CrCl &lt;50 mL/minute), compared to patients with normal renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Reduced renal function in elderly patients may reduce ara-G clearance.</p>
<p style="text-indent:-2em;margin-left:2em;">Race/ethnicity: Mean clearance and Vd values tended to be higher in white patients than in black patients (by ~10%). The opposite is true for ara-G; mean apparent clearance and Vd values tended to be lower in white patients than in black patients (by ~15% to 20%).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038862"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Arranon G</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Atriance | Atrians</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Artiance | Atriance</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Atriance</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs‚ÄîHandling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference">
                  Arranon (nelarabine) (prescribing information). East Hanover, NJ: Novartis Pharmaceuticals; July 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Atriance.1">
<a name="Atriance.1"></a>Atriance (nelarabine) [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15908649">
<a name="15908649"></a>Berg SL, Blaney SM, Devidas M, et al, ‚ÄúPhase II Study of Nelarabine (Compound 506U78) in Children and Young Adults With Refractory T-Cell Malignancies: A Report from the Children‚Äôs Oncology Group,‚Äù <i>J Clin Oncol</i>, 2005, 23(15):3376-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nelarabine-pediatric-drug-information/abstract-text/15908649/pubmed" id="15908649" target="_blank">15908649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20528871">
<a name="20528871"></a>Commander LA, Seif AE, Insogna IG, et al, ‚ÄúSalvage Therapy With Nelarabine, Etoposide, and Cyclophosphamide in Relapsed/Refractory Paediatric T-Cell Lymphoblastic Leukaemia and Lymphoma,‚Äù <i>Br J Haematol</i>, 2010, 150(3):345-351.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nelarabine-pediatric-drug-information/abstract-text/20528871/pubmed" id="20528871" target="_blank">20528871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17344466">
<a name="17344466"></a>DeAngelo DJ, Yu D, Johnson JL, et al, ‚ÄúNelarabine Induces Complete Remissions in Adults With Relapsed or Refractory T-Lineage Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Cancer and Leukemia Group B Study 19801,‚Äù <i>Blood</i>, 2007, 109(12):5136-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nelarabine-pediatric-drug-information/abstract-text/17344466/pubmed" id="17344466" target="_blank">17344466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11304766">
<a name="11304766"></a>Gandhi V, Plunkett W, Weller S, et al, "Evaluation of the Combination of Nelarabine and Fludarabine in Leukemias: Clinical Response, Pharmacokinetics, and Pharmacodynamics in Leukemia Cells," <i>J Clin Oncol</i>, 2001, 19(8):2142-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nelarabine-pediatric-drug-information/abstract-text/11304766/pubmed" id="11304766" target="_blank">11304766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21715318">
<a name="21715318"></a>G√∂kbuget N, Basara N, Baurmann H, et al, ‚ÄúHigh Single-Drug Activity of Nelarabine in Relapsed T-Lymphoblastic Leukemia/Lymphoma Offers Curative Option With Subsequent Stem Cell Transplantation,‚Äù <i>Blood</i>, 2011, 118(13):3504-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nelarabine-pediatric-drug-information/abstract-text/21715318/pubmed" id="21715318" target="_blank">21715318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol.</i> 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nelarabine-pediatric-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nelarabine-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kaiser.1">
<a name="Kaiser.1"></a>Kaiser J, Kr√§mer I. Physico-chemical stability of nelarabine infusion solutions in EVA infusion bags. <i>EJHP Science</i>. 2011;17(1):7-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nelarabine-pediatric-drug-information/abstract-text/Kaiser.1/pubmed" id="Kaiser.1" target="_blank">Kaiser.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10694549">
<a name="10694549"></a>Kisor DF, Plunkett W, Kurtzberg J, et al, ‚ÄúPharmacokinetics of Nelarabine and 9-beta-D-Arabinofuranosyl Guanine in Pediatric and Adult Patients During a Phase I Study of Nelarabine for the Treatment of Refractory Hematologic Malignancies,‚Äù <i>J Clin Oncol</i>, 2000, 18(5):995-1003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nelarabine-pediatric-drug-information/abstract-text/10694549/pubmed" id="10694549" target="_blank">10694549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15908652">
<a name="15908652"></a>Kurtzberg J, Ernst TJ, Keating MJ, et al, "Phase I Study of 506U78 Administered on a Consecutive 5-Day Schedule in Children and Adults With Refractory Hematologic Malignancies," <i>J Clin Oncol</i>, 2005, 23(15):3396-403.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nelarabine-pediatric-drug-information/abstract-text/15908652/pubmed" id="15908652" target="_blank">15908652</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24 Suppl 6:vi160-167.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nelarabine-pediatric-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed August 27, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25755211">
<a name="25755211"></a>Winter SS, Dunsmore KP, Devidas M, et al. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. <i>Pediatr Blood Cancer</i>. 2015;62(7):1176-1183.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nelarabine-pediatric-drug-information/abstract-text/25755211/pubmed" id="25755211" target="_blank">25755211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30138085">
<a name="30138085"></a>Winter SS, Dunsmore KP, Devidas M, et al. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization [published correction appeared in: <i>J Clin Oncol</i>. 2019;37(9):761]. <i>J Clin Oncol</i>. 2018;36(29):2926-2934. doi: 10.1200/JCO.2018.77.7250.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nelarabine-pediatric-drug-information/abstract-text/30138085/pubmed" id="30138085" target="_blank">30138085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28771663">
<a name="28771663"></a>Zwaan CM, Kowalczyk J, Schmitt C, et al. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study. <i>Br J Haematol</i>. 2017;179(2):284-293.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nelarabine-pediatric-drug-information/abstract-text/28771663/pubmed" id="28771663" target="_blank">28771663</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12993 Version 279.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
